Introduction
Adjuvant endocrine therapy is indicated in almost all women whose tumors show evidence of endocrine responsiveness, defined as the presence of any detectable level of estrogen receptors (ER). Patients with tumors \1 cm in size, without axillary node involvement or other signs of metastatic potential might be spared from adjuvant endocrine therapy [1] . Nevertheless, young women with breast cancer represent a particular therapeutic challenge, among other reasons because breast tumors in young women tend to have higher tumor grade at diagnosis, higher mitotic rate and lymph node involvement, and less hormone receptor expression [2] . Furthermore, in some studies the role of adjuvant therapy is not clear due to the inclusion of patients with ER-negative disease [3] . This review will focus on endocrine therapy for patients younger than 40 years old. Patients between 40 and 50 years old are also a challenge because they may become amenorrheic with chemotherapy. In this specific subgroup of patients, several consensuses have been proposed. Figure 1 summarizes a consensus statement launched by a panel of experts in Spain [4] .
Endocrine therapeutic options in young women
Around 60% of women younger than 50 years have ER-positive disease compared with 80% of women in postmenopausal status [5] , which means that more than half of all premenopausal women with early breast cancer could benefit from adjuvant endocrine therapy. Also, there is evidence suggesting that young women with ER-positive disease treated with adjuvant cytotoxic therapy alone have a significantly worse prognosis than women of the same age with ER-negative disease [6, 7] . Consequently, additional endocrine therapy should be strongly considered in this age group.
Tamoxifen therapy in young women
Tamoxifen is a first-generation selective ER modulator that has a predominantly antagonistic effect in the breast and breast cancer cells. Traditionally, tamoxifen has been the standard of care for premenopausal women with early stage ER-positive breast cancer. Results from the latest metaanalysis by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) [8] confirmed that allocation to approximately 5 years of adjuvant tamoxifen in women with ER-positive or ER-unknown disease resulted in a reduction in the annual recurrence rate of 41% (risk ratio 0.59; P = 0.03) and the mortality rate of approximately 30% (risk ratio 0.66; P = 0.04), largely irrespective of the use of chemotherapy, age, progesterone receptor status, or other tumor characteristics. This benefit was observed in women under 40 years of age (risk ratio 0.56; P = 0.10) and in patients aged 41-49 years (risk ratio 0.71; P = 0.07). In absolute terms, tamoxifen reduced by almost 10% the risk of relapse at 5 years.
Other interesting findings of this meta-analysis were that (i) the proportional risk reductions produced by tamoxifen were little affected by nodal status; (ii) 5 years of tamoxifen were significantly more effective than 1-2 years of tamoxifen, resulting in a reduction in the risk of recurrence of 18% (risk ratio 0.82; P = 0.03) and risk of death of 9% (risk ratio 0.91; P = 0.04) in women allocated to 5 years instead of 1-2; and (iii) the combination of tamoxifen with cytotoxic therapy is superior to tamoxifen therapy alone in patients younger than 50 years with ER-positive disease, regardless of the timing of tamoxifen administration in relation to cytotoxic therapy [8] .
Further increases in the duration of tamoxifen therapy have not demonstrated additional clinical benefit, and have been associated with increased toxicity. The adjuvant tamoxifen-to offer more? (aTTom) [9] and ''adjuvant tamoxifen-longer against shorter'' (ATLAS) [10] trials are assessing the benefits and risks of prolonging adjuvant tamoxifen by at least 5 years. Preliminary results indicate that continuing tamoxifen beyond the first 5 years produces discrete reductions in the rate of recurrences, but does not seem to improve overall survival. Regarding timing, based on results from the Southwest Oncology Group Intergroup Trial S8814 (INT-100) [11] , the current practice is to administer tamoxifen sequentially after adjuvant cytotoxic therapy.
Serious adverse events of tamoxifen therapy include an increased incidence of thromboembolic disease and uterine cancers, although mortality is not significantly increased [8] .
Ovarian function suppression
Ovaries are the main site of estrogen production in premenopausal women. Therefore, ovarian ablation/suppression is an effective endocrine therapeutic option to consider in young women with ER-positive disease. However, the timing and optimal duration of treatment are still a matter of debate and research.
In the EBCTCG overview [8] , which included 7,601 women aged 50 years or less with ER-positive or ERunknown disease randomized into ovarian ablation/suppression trials, these treatments were associated with a decrease in the rate of recurrence and breast cancer mortality of 30%, and a 15-year absolute decrease in risk of 4%. No significant differences were detected in the effects of ovarian ablation from those of ovarian suppression, nor in the risk reduction for women \40 years from that of women who were 40-49 years of age. Interestingly, in any age range, outcome did not improve in women who had received concurrent adjuvant cytotoxic therapy. A possible explanation for this finding could be the ability of cytotoxic therapy to permanently reduce ovarian activity, thereby limiting the benefits provided by other ovarian treatments.
In order to determine the true benefits of ovarian suppression with luteinizing hormone-releasing hormone LHRH agonist versus no systemic therapy (n = 338, four trials)
The use of an LHRH agonist alone did not have a significant effect on death after recurrence or death from any cause. However, a trend toward a reduction in the risk of recurrence was observed (HR 0.72; 95% CI 0.49-1.04; P = 0.08). This result is in line with the results of the EBCTCG overview [8] , although the small sample size and the relatively short duration of treatment (for a median of 2 years) could have affected the statistical power of the analysis.
LHRH agonist plus tamoxifen versus tamoxifen (n = 1013, five trials)
The addition of LHRH agonist to tamoxifen did not improve the outcome of tamoxifen alone. However, there was a trend toward a lower recurrence rate when used together (HR 0.85; 95% CI 0.67-1.09; P = 0.20) and in the absence of other systemic therapy, significant reductions in recurrence and death from any cause were obtained. Again, the small sample size may have affected the statistical power of the analysis.
LHRH agonist versus cytotoxic therapy (n = 3184, four trials)
No differences were observed in the risk of recurrence (HR 1.04) or death (HR 0.93) from breast cancer. In addition, no differences were observed in patients younger than 40 years. However, the extent of the results must be analyzed taking into account that the majority of cytotoxic regimens did not involve taxanes, and none of the treatment arms included tamoxifen.
LHRH agonist plus tamoxifen versus cytotoxic therapy (n = 1577, three trials)
Compared with cytotoxic therapy, the combination of LHRH plus tamoxifen did not significantly decrease the rate of recurrence or death from any cause, although a trend in favor of endocrine therapy was observed (HR 0.9; 95% CI 0.75-1.08; P = 25). Again, major criticisms of this analysis are the lack of tamoxifen in all the treatment arms, and the use of non-taxane-based cytotoxic regimens in the three studies that were analyzed [cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) was used in two studies and 5-fluorouracil, epirubicin, and cyclophosphamide in the other one].
LHRH agonist plus cytotoxic therapy plus tamoxifen (n = 1577, 11 trials)
An analysis of a very heterogeneous group from 11 trials in women aged 40 years or younger seemed to show that the addition of an LHRH agonist to cytotoxic therapy with or without tamoxifen significantly reduced the rates of recurrence by 12% and death by 15% from any cause. However, a sub-analysis of patients according to age showed that the benefit was restricted to women aged 40 years or younger, suggesting that the benefits of LHRH agonists are restricted to young patients who do not develop chemotherapy-induced amenorrhea. This observation is in accordance with the results from the INT 0101 study. In this trial, the addition of an LHRH agonist and tamoxifen for 5 years to chemotherapy with 5-fluorouracil, adriamycin, and cyclophosphamide (FAC) increased disease-free survival compared to FAC alone or FAC plus an LHRH analog in node positive premenopausal women. However, the addition of an LHRH agonist to FAC without tamoxifen was associated to a significant increase in diseasefree survival only in patients younger than 40 years, reinforcing the concept of the benefit of LHRH agonists in patients not becoming amenorrheic after chemotherapy [13] .
Another important study not included in the abovementioned meta-analysis, was the ''International Adjuvant Breast Cancer Ovarian Ablation or Suppression Trial.'' In this trial, 2144 pre-or peri-menopausal women were randomized to tamoxifen with or without ovarian ablation or suppression. The majority of patients (80%) had received CMF-based chemotherapy. Although no significant differences were observed in disease-free survival or overall survival, the results are largely limited by the high rate of unknown hormonal receptor status (40%) and the rate of ER-negative patients (20%) [14] .
The abrupt interruption of ovarian function is a significant problem in young premenopausal patients. Adverse events may include severe menopause-related signs and symptoms, psychological distress, impaired quality of life, sexual dysfunction, changes in personal and family relationships, and bone loss [15] [16] [17] . The ongoing suppression of ovarian function trial (SOFT) is addressing the question of whether younger premenopausal patients experience worse side effects from ovarian suppression/ablation than older premenopausal patients [18] .
Aromatase inhibitors
Aromatase inhibitors (AIs) are part of the standard adjuvant endocrine therapy in postmenopausal women.
However, their role in younger women remains unclear. AIs alone are contraindicated in premenopausal patients because of a reduced feedback to the hypothalamus, which increases the secretion of LHRH and consequently stimulates ovarian function [1] . Furthermore, in women who have experienced chemotherapy-induced menopause, the use of AIs maybe associated with a return of ovarian function, and even pregnancy [19] .
In young women with ER-positive disease who are unable to tolerate tamoxifen, or in whom this therapy is contraindicated, AIs may be administered together with ovarian suppression [1] . The question of whether premenopausal patients obtain more benefit from tamoxifen alone, from tamoxifen plus ovarian suppression or from exemestane plus ovarian suppression is being further explored in the SOFT and the Tamoxifen and Exemestane Trial (TEXT) [18] .
Conclusions
At this time, tamoxifen is the standard of care for young premenopausal women with ER-positive disease, and until further data from the aTTom and ATLAS trials are available, the standard duration of tamoxifen therapy remains 5 years. Currently, there is no evidence that ovarian suppression/ablation is superior to tamoxifen, except perhaps in women who have not developed chemotherapy-induced menopause. Some women are being offered treatment with ovarian suppression in association with AI therapy, mostly because of intolerance or contraindications for tamoxifen. Nevertheless, confirmation of the benefits and risks of this association awaits results from the SOFT and TEXT trials. 
